Several psychiatric medications are associated with weight loss, either as a direct effect or a common side effect. The most well-known is bupropion, an antidepressant that consistently produces weight loss in clinical trials. Stimulant medications prescribed for ADHD, certain mood stabilizers, and even a few antipsychotics round out the list, though each works through different mechanisms and carries different trade-offs.
Bupropion: The Antidepressant Most Linked to Weight Loss
Bupropion stands apart from other antidepressants. It works by increasing dopamine and norepinephrine activity in the brain, which reduces appetite and cravings rather than stimulating them the way many other antidepressants do. In a controlled trial of overweight and obese women, those taking bupropion lost an average of 6.2% of their body weight over eight weeks, compared to 1.6% in the placebo group. Two-thirds of the bupropion group lost more than 5% of their starting weight. Among those who continued treatment for 24 weeks, weight loss reached nearly 13%, with about three-quarters of that coming from fat rather than muscle or bone.
Bupropion is also one half of a combination weight-loss medication paired with naltrexone, a drug that blocks certain reward signals in the brain. In a 56-week trial, participants taking the combination alongside a behavioral program lost 9.3% of their body weight on average, compared to 5.1% with the behavioral program alone. About 42% of those on the combination lost 10% or more of their starting weight.
Stimulants for ADHD
Stimulant medications like methylphenidate and amphetamine-based drugs are well known for suppressing appetite. They work by reducing the reuptake of dopamine and norepinephrine, which enhances signaling in the brain’s reward pathways. This increased dopamine activity dampens both hunger and the drive to eat for pleasure, which is why decreased appetite is one of the most commonly reported side effects in people taking stimulants for ADHD.
Weight loss from stimulants is typically most noticeable in the first few months of treatment. For children and adolescents, this appetite suppression can be significant enough that doctors monitor growth closely. In adults, the effect tends to be less dramatic but still consistent. Lisdexamfetamine is notable because it’s the only medication FDA-approved specifically for moderate to severe binge eating disorder, where its appetite-suppressing properties serve a therapeutic purpose beyond ADHD management. However, stimulants carry a meaningful risk of misuse and can raise heart rate and blood pressure, which limits their use in people with cardiovascular concerns.
Topiramate: A Mood Stabilizer That Reduces Weight
Topiramate is prescribed for epilepsy, migraine prevention, and sometimes as an add-on for mood disorders. Unlike most mood stabilizers, which tend to cause weight gain, topiramate reliably produces weight loss. In a six-month dose-ranging trial, participants lost between 5% and 6.3% of their body weight depending on the dose, compared to 2.6% with placebo. The weight loss effect appeared even at the lowest dose tested (64 mg/day) and didn’t increase much beyond moderate doses.
The trade-off with topiramate is cognitive. Many people report mental fogginess, word-finding difficulty, and trouble concentrating. Other side effects include fatigue, coordination problems, and in rare cases, a type of metabolic imbalance called acidosis. These cognitive effects are significant enough that topiramate earned the informal nickname “dopamax” among patients. For people already dealing with depression or cognitive symptoms from their psychiatric condition, this side effect profile can be a dealbreaker.
SSRIs: Short-Term Loss, Long-Term Gain
Some SSRIs, particularly fluoxetine, cause modest weight loss in the first few months of treatment. This sometimes leads people to think of fluoxetine as a weight-loss-friendly antidepressant, but the picture changes with time. A meta-analysis found that the initial weight loss effect of SSRIs disappears after about four months of use. Many people then experience gradual weight gain over the following months and years. Fluoxetine is FDA-approved for bulimia nervosa, but that approval relates to its effect on binge-purge cycles rather than weight management.
If you’re starting an SSRI and notice some early weight loss, it’s reasonable to expect that trend won’t continue. Among antidepressants, bupropion remains the most reliable option for people concerned about weight.
Antipsychotics That Avoid Weight Gain
Most antipsychotics cause significant weight gain, but a few are considered weight-neutral, meaning they don’t differ meaningfully from placebo. Ziprasidone and lurasidone consistently show the lowest risk. In a large meta-analysis using six-week data, both caused no significant weight change compared to placebo. Aripiprazole and amisulpride also fall on the lower end of the spectrum, with only minor weight gain reported.
It’s worth noting that none of these antipsychotics reliably cause weight loss. They’re better understood as options that don’t add to the problem. Interestingly, a proportion of patients taking ziprasidone and aripiprazole did lose more than 7% of their body weight in clinical trials, but this wasn’t the norm. For someone switching from a weight-promoting antipsychotic like olanzapine, moving to ziprasidone or lurasidone can result in weight loss simply because the previous drug’s effect is removed.
Why These Medications Affect Weight Differently
The common thread among weight-loss-associated psych meds is their effect on dopamine and norepinephrine. Bupropion, stimulants, and to some extent topiramate all increase the activity of these neurotransmitters, which suppresses appetite and reduces reward-driven eating. Medications that increase serotonin activity (most SSRIs) or block histamine and serotonin receptors (many antipsychotics) tend to do the opposite, increasing hunger and promoting fat storage.
This isn’t a clean rule. Individual responses vary considerably based on genetics, baseline metabolism, diet, and other medications. Some people lose weight on drugs that typically cause gain, and vice versa. But the dopamine/norepinephrine pattern holds strongly enough to guide prescribing decisions when weight is a concern.
Practical Considerations
If weight is a priority in your treatment plan, it’s a legitimate factor to raise with your prescriber. Bupropion is often a first-line choice for depression when weight gain would be particularly harmful, whether for metabolic health or motivation to stay on treatment. For people already on a medication that’s causing weight gain, switching to a weight-neutral or weight-loss-associated alternative is a common strategy, though it needs to be weighed against how well the current medication controls psychiatric symptoms.
No psychiatric medication should be taken primarily for weight loss unless it’s specifically indicated for that purpose (like lisdexamfetamine for binge eating disorder or the bupropion-naltrexone combination for obesity). Stimulants carry abuse potential, topiramate can impair thinking, and even bupropion has its own side effect profile including a small risk of seizures at higher doses. The weight effects of these drugs are real and well-documented, but they work best when the primary psychiatric indication aligns with the metabolic benefit.